Milestone Approvals in Sickle Cell Disease (SCD): FDA Approves Two Therapies before Pfizer's GBT601 Disclosure

Ahead of Pfizer's disclosure of the Phase II/III preliminary study results of GBT601, the field of sickle cell disease (SCD) achieved two milestone approvals. On December 8th, the FDA approved Casgevy (exagamglogene autotemcel), a gene editing therapy developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics. On the same day, Bluebird Bio, a prominent gene therapy research company, also received FDA approval for their therapy, Lyfgenia (lovotibeglogene autotemcel).

Milestone Approvals in SCD:
Both therapies have identical indications and compete directly with each other. They are approved for the treatment of patients aged 12 and above with recurrent vaso-occlusive crises (VOC) in sickle cell disease (SCD).

Significant Price Difference:
However, there is a substantial difference in pricing between the two therapies. According to publicly available information, Bluebird Bio's Lyfgenia gene therapy is currently priced at $3.1 million, while the competitor Casgevy gene editing therapy is priced at $2.2 million.

The FDA approvals of Casgevy and Lyfgenia mark significant milestones in the field of sickle cell disease. These therapies offer new treatment options for patients with recurrent VOC in SCD. However, the notable disparity in pricing between the two therapies raises important considerations regarding accessibility and affordability. The competition between these innovative treatments highlights the ongoing efforts to improve the management and outcomes of SCD for patients worldwide.